Recent studies have supported a role for amyloid positron emission tomography (PET) imaging in distinguishing Alzheimer’s disease (AD) pathology from other pathological protein accumulations leading to dementia. We investigated the clinical utility of amyloid PET in the differential diagnosis of atypical dementia cases and its impact on caregivers. Using the amyloid tracer 18F-NAV4694, we prospectively scanned 28 patients (mean age 59.3 y, s.d. 5.8; mean MMSE 21.4, s.d. 6.0) with an atypical dementia syndrome. Following a comprehensive diagnostic workup (i.e., history taking, neurological examination, blood tests, neuropsychological evaluation, MRI, and FDG-PET), no certain diagnosis could be arrived at. Amyloid PET was then conducted and classified as positive or negative. Attending physicians were asked to evaluate whether this result led to a change in diagnosis or altered management. They also reported their degree of confidence in the diagnosis. Caregivers were met after disclosure of amyloid PET results and completed a questionnaire/interview to assess the impact of the scan. Our cohort was evenly divided between positive (14/28) and negative (14/28) 18F-NAV4694 cases. Amyloid PET resulted in a diagnostic change in 9/28 cases (32.1%: 17.8% changed from AD to non-AD, 14.3% from non-AD to AD). There was a 44% increase in diagnostic confidence. Altered management occurred in 71.4% (20/28) of cases. Knowledge of amyloid status improved caregivers’ outcomes in all domains (anxiety, depression, disease perception, future anticipation, and quality of life). This study suggests a useful additive role for amyloid PET in atypical cases with an unclear diagnosis beyond the extensive workup of a tertiary memory clinic. Amyloid PET increased diagnostic confidence and led to clinically significant alterations in management. The information gained from that test was well received by caregivers and encouraged spending quality time with their loved ones.
BergeronD, BensaïdaneM, LaforceRJ (2015) Untangling Alzheimer’s disease clinicoanatomical heterogeneity through selective network vulnerability – an effort to understand a complex disease. Curr Alzheimer Res, doi: 10.2174/1567205013666151116125155
2.
McKhannG, KnopmanD, ChertkowH, HymanB, JackC, KawasC, KlunkW, KoroshetzW, ManlyJ, MayeuxR, MohsR, MorrisJ, RossorM, ScheltensP, CarrilloM, ThiesB, WeintraubS, PhelpsC (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement7, 263–269.
3.
OssenkoppeleR, PijnenburgYA, PerryDC, Cohn-SheehyBI, ScheltensNM, VogelJW, KramerJH, van der VliesAE, JoieRL, RosenHJ, van der FlierWM, GrinbergLT, RozemullerAJ, HuangEJ, van BerckelBN, MillerBL, BarkhofF, JagustWJ, ScheltensP, SeeleyWW, RabinoviciGD (2015) The behavioural/dysexecutive variant of Alzheimer’s disease: Clinical, neuroimaging and pathological features. Brain138, 2732–2749.
4.
BeachTG, MonsellSE, PhillipsLE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol71, 266–273.
5.
GrundmanM, PontecorvoMJ, SallowaySP, DoraiswamyPM, FleisherAS, SadowskyCH, NairAK, SiderowfA, LuM, AroraAK (2013) Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord27, 4–15.
6.
WolkDA, PriceJC, MadeiraC, SaxtonJA, SnitzBE, LopezOL, MathisCA, KlunkWE, DeKoskyST (2012) Amyloid imaging in dementias with atypical presentation. Alzheimers Dement8, 389–398.
7.
ClarkC, PontecorvoM, BeachT, BedellB, ColemanR, DoraiswamyP, FleisherA, ReimanE, SabbaghM, SadowskyC, SchneiderJ, AroraA, CarpenterA, FlitterM, JoshiA, KrautkramerM, LuM, MintunM, SkovronskyD (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study. Lancet Neurol11, 669–678.
OssenkoppeleR, PrinsND, PijnenburgYA, LemstraAW, van der FlierWM, AdriaanseSF, WindhorstAD, HandelsRL, WolfsCA, AaltenP, VerheyFR, VerbeekMM, van BuchemMA, HoekstraOS, LammertsmaAA, ScheltensP, van BerckelBN (2013) Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement9, 414–421.
11.
Sanchez-JuanP, GhoshPM, HagenJ, GesierichB, HenryM, GrinbergLT, O’NeilJP, JanabiM, HuangEJ, TrojanowskiJQ, VintersHV, Gorno-TempiniM, SeeleyWW, BoxerAL, RosenHJ, KramerJH, MillerBL, JagustWJ, RabinoviciGD (2014) Practical utility of amyloid and FDG-PET in an dementia academic center. Neurology82, 230–238.
12.
BensaïdaneM, FortinM, DamasseG, ChenardM, DionneC (2014) Clinical utility of amyloid imaging in a complex case of corticobasal syndrome presenting with psychiatric symptoms. J Neurol Disord2, 2.
13.
ZannasAS, DoraiswamyPM, ShpanskayaKS, MurphyKR, PetrellaJR, BurkeJR, WongTZ (2014) Impact of 18F-florbetapir PET imaging of beta-amyloid neuritic plaque density on clinical decision-making. Neurocase20, 466–473.
14.
MitsisE, BenderH, KostakogluL, MachacJ, MartinJ, WoehrJ, SewellM, AloysiA, GoldsteinM, LiC, SanoM, GandyS (2014) A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: Impact on quality of life, decision making, and disposition. Mol Neurodegener9, 10.
15.
ZwanMD, BouwmanF, KonijnenburgE, van der FlierWM, LammertsmaAA, Van BerckelBNM, ScheltensP (2015) Diagnostic impact of [18f] flutemetamol amyloid imaging in young onset dementia (abstract #3407), Alzheimers Dement11, P3–P4.
16.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM (2013) Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med54, 476–490.
17.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, HedrickS, PappasV, CarrilloMC, HartleyDM (2013) Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. J Nucl Med54, 1011–1013.
18.
RabinoviciG, RosenH, AlkalayA, KornakJ, FurstA, AgarwalN, MorminoE, O’NeilJ, JanabiM, KarydasA, GrowdonM, JangJ, HuangE, DearmondS, TrojanowskiJ, GrinbergL, Gorno-TempiniM, SeeleyW, MillerB, JagustW (2011) Amyloid versus FDG PET in the differential diagnosis of AD and FTLD. Neurology77, 2034–2042.
19.
JagustW, ReedB, MungasD, EllisW, DeCarliC (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?Neurology69, 871–877.
20.
LaforceR, ButeauJ, PaquetN, VerretL, HoudeM, BouchardR (2010) The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study. Am J Alzheimers Dis Other Dement25, 324–332.
21.
GauthierS, PattersonC, ChertkowH, GordonM, HerrmannN, RockwoodK, Rosa-NetoP, SoucyJP (2012) Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J15, 120–126.
22.
CselenyiZ, JonhagenME, ForsbergA, HalldinC, JulinP, SchouM, JohnstromP, VarnasK, SvenssonS, FardeL (2012) Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med53, 415–424.
23.
JureusA, SwahnBM, SandellJ, JeppssonF, JohnsonAE, JohnstromP, NeelissenJA, SunnemarkD, FardeL, SvenssonSP (2010) Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem114, 784–794.
24.
RoweCC, PejoskaS, MulliganRS, JonesG, ChanJG, SvenssonS, CselenyiZ, MastersCL, VillemagneVL (2013) Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med54, 880–886.
25.
WolkDA (2013) Amyloid imaging in atypical presentations of Alzheimer’s disease. Curr Neurol Neurosci Rep13, 412.
26.
MendezM, ShapiraJ, McMurtrayA, LichtE (2007) Preliminary findings: Behavioral worsening on donepezil inpatients with frontotemporal dementia. Am J Geriatr Psychiatry15, 84–87.
ArciniegasDB, AndersonCA (2013) Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia, J Neuropsychiatry Clin Neurosci25, E25–E26.
29.
BarthelH, GertzH-J, DreselS, PetersO, BartensteinP, BuergerK, HiemeyerF, Wittemer-RumpSM, SeibylJ, ReiningerC (2011) Cerebral amyloid-β PET with florbetaben (18 F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol10, 424–435.
30.
PalmqvistS, ZetterbergH, BlennowK, VestbergS, AndreassonU, BrooksDJ, OweniusR, HagerstromD, WollmerP, MinthonL, HanssonO (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol71, 1282–1289.
31.
VerweyNA, van der FlierWM, BlennowK, ClarkC, SokolowS, De DeynPP, GalaskoD, HampelH, HartmannT, KapakiE, LannfeltL, MehtaPD, ParnettiL, PetzoldA, PirttilaT, SalehL, SkinningsrudA, SwietenJC, VerbeekMM, WiltfangJ, YounkinS, ScheltensP, BlankensteinMA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem46, 235–240.
32.
MattssonN, ZetterbergH, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaSK, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekM, TsolakiM, MulugetaE, RosenE, AarslandD, VisserPJ, SchroderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, PirttilaT, WallinA, JonhagenME, MinthonL, WinbladB, BlennowK (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. J Am Med Assoc302, 385–393.
33.
BlennowK, DuboisB, FaganAM, LewczukP, de LeonMJ, HampelH (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement11, 58–69.
34.
ElsonP (2006) Do older adults presenting with memory complaints wish to be told if later diagnosed with Alzheimer’s disease?Int J Geriatr Psychiatry21, 419–425.
35.
MormontE, JamartJ, JacquesD (2014) Symptoms of depression and anxiety after the disclosure of the diagnosis of Alzheimer disease. J Geriatr Psychiatry Neurol27, 231–236.
36.
JohnsonK, MinoshimaS, BohnenN, DonohoeK, FosterN, HerscovitchP, KarlawishJ, RoweC, CarrilloM, HartleyD, HedrickS, PappasV, ThiesW (2013) Appropriate use criteria for amyloid PET: A report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer’s association. Alzheimers Dement9, 1–15.
37.
LaforceRJ, Rosa-NetoP, SoucyJP, RabinoviciGD, DuboisB, GauthierS (2016) Canadian consensus guidelines on use of amyloid imaging in Canada: Update and future directions from the Specialized Task force on Amyloid imaging in Canada (STAC). Can J Neurol Sci, doi: 10.1017/cjn.2015.1401
38.
DuboisB, PadovaniA, ScheltensP, RossiA, Dell’AgnelloG (2015) Timely diagnosis for Alzheimer’s disease: A literature review on benefits and challenges. J Alzheimers Dis49, 617–631.
